Explore 3 Stock Ideas & Industry Insights Download Free Report

International Biotechnology Trust plc

Healthcare GB IBT

966.0GBX
28.00(2.99%)

Last update at 2026-06-04T15:35:00Z

Day Range

938.00970.00
LowHigh

52 Week Range

498.71998.00
LowHigh

Fundamentals

  • Previous Close 938.00
  • Market Cap307.86M
  • Volume39524
  • P/E Ratio-
  • Dividend Yield3.32%
  • Revenue TTM5.25M
  • Revenue Per Share TTM0.15
  • Gross Profit TTM 5.25M
  • Diluted EPS TTM-0.03

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Income before tax -1.14200M 39.01M 6.93M -22.32200M 28.05M
Minority interest - - - - -
Net income -1.17000M 38.88M 6.81M -22.47300M 27.89M
Selling general administrative 0.97M 1.13M 1.56M 1.22M 1.07M
Selling and marketing expenses - - - - -
Gross profit 14.38M 40.14M 8.49M -21.10400M 29.12M
Reconciled depreciation - - - - -
Ebit - 37.90M - -17.28100M 28.20M
Ebitda -0.02100M 39.55M 6.93M -21.65900M 28.05M
Depreciation and amortization - 1.66M - - -
Non operating income net other - - - - -
Operating income -0.02100M 39.55M 6.93M -21.65900M 28.05M
Other operating expenses 18.71M 3.33M 1.56M 1.22M 1.07M
Interest expense 1.94M 2.20M 1.24M 0.66M 0.22M
Tax provision 0.03M 0.14M 0.12M 0.15M 0.16M
Interest income 0.23M 0.22M 0.02M 0.00000M 0.00000M
Net interest income -1.71200M -1.98000M -1.21900M -0.66300M -0.21800M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.03M 0.14M 0.12M 0.15M 0.16M
Total revenue 18.69M 42.34M 8.49M -21.10400M 29.12M
Total operating expenses 14.40M 1.13M 1.56M 1.22M 1.07M
Cost of revenue 4.30M 2.20M - - 2.97M
Total other income expense net -1.12100M -0.54200M - -0.66300M -0.21800M
Discontinued operations - - - - -
Net income from continuing ops -1.17000M 38.88M 6.81M -22.47300M 27.89M
Net income applicable to common shares - - - -22.47300M 27.89M
Preferred stock and other adjustments - - - - -
Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Total assets 284.04M 308.15M 304.87M 326.92M 347.83M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets -15.04600M 0.11M - - -
Total liab 34.63M 25.89M 34.55M 42.03M 24.06M
Total stockholder equity 249.41M 282.26M 270.32M 284.89M 323.77M
Deferred long term liab - - - - -
Other current liab -29.60700M -22.82700M -0.14300M -1.19600M -2.19100M
Common stock 10.35M 10.35M 10.35M 10.35M 10.35M
Capital stock 10.35M 10.35M 10.35M 10.35M 10.35M
Retained earnings -58.08600M -54.02700M - -46.66100M 252.07M
Other liab - - - - -
Good will - - - - -
Other assets 284.04M 308.15M 0.25M 0.15M 0.10M
Cash 14.98M 10.43M - 0.00000M 1.56M
Cash and equivalents - - - - -
Total current liabilities - 1.87M 0.14M 1.20M 2.19M
Current deferred revenue - - - - -
Net debt 14.63M 12.39M 32.47M 39.98M 20.31M
Short term debt 29.61M 22.83M - - 21.87M
Short long term debt - - - - -
Short long term debt total 29.61M 22.83M 32.47M 39.98M 21.87M
Other stockholder equity 29.87M 294.46M 259.97M 274.54M 313.43M
Property plant equipment - - - - -
Total current assets - 10.65M 2.72M 13.34M 2.40M
Long term investments 268.92M 297.51M 301.90M 313.43M 345.34M
Net tangible assets - - - 284.89M 323.77M
Short term investments - - - - -
Net receivables 0.07M 0.11M 2.72M 13.34M 0.84M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 2.06M 1.87M 0.14M 1.20M 2.19M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 267.28M 31.48M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - -297.50700M -301.90400M -313.42900M -345.33600M
Deferred long term asset charges - - - - -
Non current assets total - 297.51M 301.90M 313.43M 345.34M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Investments - - - - -
Change to liabilities - - - 0.26M 1.48M
Total cashflows from investing activities - - - - -
Net borrowings 7.76M 24.73M - - -
Total cash from financing activities -23.92500M -2.19800M -21.38500M -16.41300M 11.99M
Change to operating activities - - - 19.01M -43.11300M
Net income -1.17000M 38.88M 6.93M -22.32200M 28.05M
Change in cash 4.55M 42.91M 7.50M -19.66400M -2.54000M
Begin period cash flow 10.43M -32.47400M -39.97600M -20.31200M -17.77200M
End period cash flow 14.98M 10.43M -32.47400M -39.97600M -20.31200M
Total cash from operating activities 28.63M 45.35M 27.30M 1.12M -14.53300M
Issuance of capital stock - - - 0.00000M 23.56M
Depreciation - - - - -
Other cashflows from investing activities - -50.46300M - - -
Dividends paid 11.20M 10.77M 11.41M 12.88M 11.56M
Change to inventory - - - - -
Change to account receivables 0.00900M 0.01M - -0.03300M -0.78100M
Sale purchase of stock -20.49000M -16.16000M -9.97800M -3.53400M 23.56M
Other cashflows from financing activities - - - - -
Change to netincome - - - 4.36M 4.36M
Capital expenditures 28.63M 45.35M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.77M -0.73200M 22.06M 0.23M -42.41800M
Stock based compensation - - - - -
Other non cash items 28.03M 7.21M -1.69900M 23.22M -0.16200M
Free cash flow 28.63M 45.35M 27.30M 1.12M -14.53300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x)
IBT
International Biotechnology Trust plc
28.00 2.99% 966.00 - 714.29 16.40 1.20 15.60
GNS
Genus PLC
38.00 1.70% 2274.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd
5.50 4.09% 140.00 - - 4.71 2.50 4.23 -8.8899
OXB
Oxford BioMedica PLC
28.00 4.90% 600.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC
- -% 70.00 - - 2849.46 1929.84 2525.51 -12.0368

Reports Covered

Stock Research & News

Profile

International Biotechnology Trust plc specializes in investments in development stage and late stage companies. The majority of the fund's assets are generally invested in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies. It makes long only investments. It prefers to invest in quoted or unquoted biotechnology and life sciences companies focused on drug discovery and development and in related sectors such as microbiology, life sciences, pharmaceutical research and development, gene research and development, medical devices or healthcare services. The fund seeks to invest in companies engaged in development and/or commercialization of a product, device or enabling technology and also invests in the therapeutic sub-sector. The fund also prefers to invest in companies with strong growth potential from the development and/or commercialization of either a biotechnology drug candidate, medical device or other enabling technology for medical research. It may also invest in specialty pharmaceuticals and life science tools. These companies can range from small private companies with strong science and people that need development funding, to large, multi-billion dollar biotechnology and medical device companies which have portfolios of products, many of which are already used in hospitals, clinics and pharmacies around the world. It makes majority of its investments in smaller and mid-capitalization quoted companies and seeks to invest up to thirty percent of the Company's assets in unquoted companies, while allowing an exposure of up to forty percent in unquoted companies (at the time of investment and after allowing for valuation write-ups and further follow-on investments). The fund typically invests in the United States, but seeks the best investments worldwide and so may also invest in Western Europe, Australia, and Asia. It typically invests between $1 million and $4 million in its portfolio companies. It exits its unquoted investments through the sale of the

International Biotechnology Trust plc

31 Gresham Street, London, United Kingdom, EC2V 7QA

Key Executives

Name Title Year Born
Ms. Lucy Costa Duarte Head of Investor Relations NA
Ms. Catherine Elizabeth Bingham M.B.A. Managing Partner 1966
Ms. Ailsa Craig Investment Mang. NA
Mr. Marek Poszepczynski M Sci Eng Investment Mang. NA
Claire Jackson Company Sec. NA
Dr. Carl Harald Janson Lead Investment Mang. NA
Ms. Catherine Elizabeth Bingham M.B.A. Managing Partner 1967
Ms. Claire Jackson Company Secretary NA
Dr. Carl Harald Janson and CEFA, M.D., Ph.D. Lead Investment Manager NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.